Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
Pharmaceutical Stock Bounces Off Record Lows
Kenvue Inc (NYSE:KVUE) stock is up 3.9% to trade at $17.62 at last check, erasing some of yesterday's losses that followed the Trump administration connection between the use of acetaminophen -- the active ingredient of the company's Tylenol pain drug -- in pregnancy and autism.
Tylenol: Kenvue's Sobering Reality
I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Despite Self Care sales weakness and ongoing litigation concerns, Tylenol continues to gain market share and new product launches are underway.
Tylenol Maker Kenvue Shares Rebound After Trump Links Drug To Autism
23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Association.
Wall Street Breakfast Podcast: Kenvue In Focus
Kenvue (KVUE) rebounds 6% premarket after sharp drop, following FDA warning on acetaminophen use during pregnancy and company defense of Tylenol's safety. Boeing (BA) secures Uzbekistan Airways' largest-ever order for up to 22 Dreamliners, supporting fleet modernization and international route expansion.
Kenvue stock rallies off record low after Trump press conference on alleged Tylenol-autism link
Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.
Tylenol-maker Kenvue shares bounce, Trump claims face pushback
Tylenol-maker Kenvue stock rose in European trading on Tuesday, even after U.S. President Donald Trump linked its popular pain medication to autism risk during pregnancy.
Kenvue takes a $1.4bn Tylenol hit
Kenvue Inc (NYSE:KVUE) shares dropped 4% at the open on Monday, erasing about $1.4 billion in market value, after a report that Trump administration officials plan to warn pregnant women against taking Tylenol unless they have a fever. The Washington Post said the guidance will claim the active ingredient, acetaminophen, is linked to autism, citing unnamed sources.
Trump administration reportedly plans to link autism to Tylenol use during pregnancy
The Trump administration is expected to make an announcement Monday linking pregnant women's use of Tylenol to autism, according to The Washington Post. Federal health officials will also reportedly highlight leucovorin as a potential autism treatment.
Kenvue CEO lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports
Kenvue's interim Chief Executive Officer Kirk Perry met Robert F. Kennedy Jr. to try and dissuade the U.S. health secretary from including Tylenol as a potential cause of autism in an upcoming report, the Wall Street Journal said on Friday, citing a person familiar with the matter.
Kenvue fights back against Tylenol safety concerns as its stock tumbles
Kenvue rushed to the defense of Tylenol, but the stock still suffered a record selloff on news that RFK Jr. will release a report linking the use of acetaminophen during pregnancy to autism.
Kenvue Can't Be Written Off Yet
Kenvue's fundamental performance looks disastrous, with revenue and margins going in the wrong direction. In that context, a 20x-plus multiple to 2025 adjusted EPS looks far too high. But a new board, new leadership, and new strategy suggest real change is on the way for a business where execution clearly is a concern.
